BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 331 filers reported holding BIO-TECHNE CORP in Q1 2018. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $352,000 | -11.8% | 1,110 | -31.1% | 0.00% | 0.0% |
Q3 2020 | $399,000 | +10.5% | 1,611 | +17.7% | 0.00% | 0.0% |
Q2 2020 | $361,000 | +161.6% | 1,369 | +117.0% | 0.00% | +100.0% |
Q1 2020 | $138,000 | 0.0% | 631 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $138,000 | +35.3% | 631 | +20.2% | 0.00% | – |
Q3 2019 | $102,000 | -2.9% | 525 | +4.0% | 0.00% | – |
Q2 2019 | $105,000 | +10.5% | 505 | +5.2% | 0.00% | – |
Q1 2019 | $95,000 | +239.3% | 480 | +140.0% | 0.00% | – |
Q4 2018 | $28,000 | -87.3% | 200 | -81.5% | 0.00% | -100.0% |
Q3 2018 | $221,000 | -40.6% | 1,083 | -56.9% | 0.00% | -50.0% |
Q2 2018 | $372,000 | +14.8% | 2,515 | 0.0% | 0.00% | +100.0% |
Q1 2018 | $324,000 | 0.0% | 2,515 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $324,000 | +6.9% | 2,515 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $303,000 | +23.7% | 2,515 | +3.9% | 0.00% | 0.0% |
Q2 2017 | $245,000 | 0.0% | 2,421 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $245,000 | +24.4% | 2,421 | +26.0% | 0.00% | 0.0% |
Q4 2016 | $197,000 | -5.7% | 1,922 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $209,000 | -5.9% | 1,922 | -2.7% | 0.00% | 0.0% |
Q2 2016 | $222,000 | +22.7% | 1,975 | +2.8% | 0.00% | 0.0% |
Q1 2016 | $181,000 | +5.2% | 1,922 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $172,000 | -2.8% | 1,922 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $177,000 | -5.9% | 1,922 | 0.0% | 0.00% | 0.0% |
Q2 2015 | $188,000 | -2.1% | 1,922 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $192,000 | +8.5% | 1,922 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $177,000 | +132.9% | 1,922 | +60.2% | 0.00% | -94.4% |
Q2 2009 | $76,000 | – | 1,200 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |